



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel. : +91-22-6622 7575 • **Fax** : +91-22-6622 7600 / 7500
Email : anuh@sk1932.com • **CIN** : L24230MH1960PLC011586
Web: www.anuhpharma.com

Date: 28th May, 2026

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
BSE Scrip Code: 506260

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Sub: Investor Presentation – Q4 FY 2025-26

Dear Sir/Madam,

With reference to the subject mentioned above and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Investor Presentation for Q4 FY 2025-26.

This intimation is also being uploaded on the Company's website at www.anuhpharma.com.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

FOR ANUH PHARMA LIMITED

MANAN VADHAN
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: As above



We Serve Since 1932

Factory : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. **Tel.:** +91-7410055574 / 75



ANUH PHARMA LTD.

Investor Presentation FY2026 (May-26)

BSE Scrip Code: 506260

Bloomberg Code: ANUH IN

Reuters

Code: ANUH.BO

www.anuhpharma.com

This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements.

The Company also disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Anuh Pharma Limited.



ANUH PHARMA LTD.

Table of content

01

FY 2026 & FY 2025 HIGHLIGHTS

02

COMPANY OVERVIEW

03

INFRASTRUCTURE

04

FUTURE OUTLOOK

05

CORPORATE SOCIAL RESPONSIBILITY



01

FY 2026 & FY 2025 HIGHLIGHTS

Message from Joint MD



Dear Shareholders, Investors and partners,

On behalf of the Board of Directors, it gives me immense pleasure to present our performance report for the fourth quarter and the financial year ended March 31, 2026. This year marks an important milestone for Anuh Pharma Ltd., highlighted by the successful completion of both the USFDA and EU GMP inspections. Our performance was driven by strong volume growth, strategic expansion into highly regulated markets, and the resilience of our operations amidst evolving macroeconomic conditions and ongoing business transformations.

Throughout the year, quality, regulatory compliance, and customer reliability remained at the centre of our operations, reinforcing our reputation as a trusted global API partner.

Financial Performance review:

For the year

Revenue (FY26) (Cr)	EBIDTA (Excl. Other Items) (FY26) (Cr)	Total Production (MT)
776 (+15.66%)	67.84 (+6.52%)	1733 (+24.99%)

For the Quarter

Revenue Q4 (Cr)	EBIDTA (Excl. Other Items) FY26 Q4 (Cr)	Total Production (MT)
201 (0.01%)	23.56 (18.32%)	426 (-0.04%)

Message from Joint MD



Revenue Growth	FY26 revenue increased by 15.66% to Rs. 776 Cr., supported by strong volume growth and expansion in regulated markets.
Profitability	The company maintained healthy profitability through operational efficiencies and an improved product mix despite global market challenges during Q4.
Manufacturing Excellence	Achieved record production volumes with consistently high plant utilization, reflecting strong operational discipline and execution capabilities.
Research & Development	Continued focus on process innovation, cost optimization, and development of high-value niche APIs to strengthen long-term competitiveness.
Regulatory Excellence	Successfully completed USFDA and EU GMP inspections, reinforcing our commitment to global quality and compliance standards.

Message from Joint MD



The path ahead:

As we look forward, the fundamental drivers of Anuh Pharma Ltd. remain stronger than ever. The extensive volume expansions across our API lines, coupled with high-value regulatory market growth, have placed us in an well-positioned for sustainable long-term growth. We continue to prioritize process innovations, cost Optimization Strategic Market Diversification focusing on export to reduce currency risk.

Strategic Outlook:

Our continued investments in compliance, operational efficiency, and capacity enhancement are creating a strong foundation for long-term sustainable growth. With increasing opportunities in regulated markets, a diversified product portfolio, and improving operational leverage, we remain confident in our ability to deliver consistent value to all stakeholders over the coming years.

Gratitude:

We want to express my deepest gratitude to all our talented employees for their relentless commitment, and to our shareholders, bankers, clients, and partners for their unwavering faith in our journey. Together, we are crafting a highly sustainable, robust, and valuable pharmaceutical enterprise.

Warm regards,


Ritesh Shah (Joint MD)

Vivek Shah (Joint MD)


Financial performance highlights (last 5 years)



Total Revenue (INR in Cr.)




EBITDA (INR in Cr.)




PBT (INR in Cr.)

PAT (INR in Cr.)




Business mix revenue contribution


Revenue Split (Rs. In Cr.)




Top 5 customers contribution



GEOGRAPHICAL EXPORT SALES FY 2026




GEOGRAPHICAL EXPORT SALES FY 2025



Product mix revenue contribution

FY25


FY26 (INR in Cr.)




Track Record




EBITDA Margin %




Net Profit Margin %



ROE (%)




ROCE (%)



Track Record




Outflow of Dividend (INR in Cr.)




Recommended by BOD, subject to members' approval


Current ratio



Debt to Equity



Cash Conversion Cycle (Days)



FY 26 and FY 25 Financial Performance



Rs. In Crores

<u>Financial Highlights</u>	3 months ended 31/03/2026	3 months ended 31/12/2025	% Change QOQ	12 months ended 31/03/2026	12 months ended 31/03/2025	% Change YoY
Operating Revenue	202.12	197.18	2.50	771.66	661.51	16.65
Operating Profit (PBT+ Dep+ Other Exps - Other Income)	44.44	38.91	14.20	145.22	138.49	4.86
% of Margin	21.99	19.73		18.82	20.93	
Other Income	(1.25)	1.79	(170.20)	4.36	9.46	(53.93)
EBITDA	18.63	20.91	(10.91)	66.08	70.36	(6.09)
% of Margin	9.22	10.60		8.56	10.64	
Interest	0.11	0.08	32.79	0.47	0.62	(23.74)
Depreciation	3.00	3.00	0.01	11.38	8.74	30.24
PBT	15.52	17.83	(12.95)	54.22	61.01	(11.12)
TAX	3.84	4.38	(12.32)	13.18	13.65	(3.50)
PAT	11.68	13.45	(13.16)	41.05	47.35	(13.32)
Reported EPS	1.17	1.34	(13.16)	4.10	4.72	(13.32)



02

COMPANY
OVERVIEW

Company Overview



The Company derived ~46% of its revenues from exports in FY26.

The Company has strong marketing partnerships with 360 customers in over 72 countries including Europe, Mexico and South Africa.

The expansion project with state of the art manufacturing facility targeted at regulated market is completed and commercial production from the said new facility started w.e.f. 21st December, 2019.

Anuh Pharma, a bulk drug manufacturing company is part of the INR 8.5bn SK Group, which employs ~2200 people across businesses such as manufacturing of pharma formulations, trading, distribution and logistics (primarily for large MNC brands)

Anuh Pharma is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension and Corticosteroids

The Company owns one manufacturing facility at Tarapur over 11,400 sq. mtrs of land (Incl. newly acquired plot of 7,800 sq. meters) and an R&D facility at Mahape spread over 10,000 sq.ft.








Journey So Far...

Year	Achievements
1989	Started manufacturing Erythromycin salts with capacity of 150 MTPA , followed by doubling the capacity to 300 MTPA in 1995.
2002	Received WHO-GMP for its facilities.
2006	Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600 MTPA.
2010	COS, EU/GMP approval for Erythromycin, Erythromycin ethyl succinate and Pyrazinamide.
2012	Acquired R&D assets of Invent Pharma- a Spanish Company and got DSIR approval.
2014	Received approval from COFEPRIS, Mexico for marketing its Erythromycin estolate, Erythromycin stearate and Erythromycin ethyl succinate.
2015	Received approval from COFEPRIS, Mexico for marketing its Chloramphenicol and Chloramphenicol Palmitate.
2015	WHO Geneva pre qualification authorities for sulphadoxine for human use.
2017	DMF approval received from UK MHRA for Erythromycin Stearate.
2018	Received certificate of GMP (WHO GMP) from FDA Maharashtra.
2019	Received approval from WHO- Geneva Pre qualification for Pyrazinamide and sulphadoxine.
2019	Received EU GMP for Erythromycin, Erythromycin ethyl succinate, Pyrazinamide, Pyrimethmine and Sulphadoxine from AEMPS Spain.
2019	Enhanced the capacity by acquiring new plot of 7800 SQMT to expand the output capacity by 600 MTPA.
2019	USFDA inspection passed successfully with zero 483 observation.

Journey So Far...

Year	Achievements
2020	Received approval from WHO Geneva prequalification for Pyrimethamine API
2023	Received CEP from EDQM for Sulphadoxine.
2023	Received CEP from EDQM for Azithromycin (Higher macrolides)
2023	Received CEP from EDQM for Gliclazide (Anti Diabetic)
2023	Enhanced the capacity from 1500 MTPA to 1800 MTPA
2024	Received approval from WHO- Geneva Pre qualification for Isoniazid (Anti TB)
2024	Received renewal of approval from WHO for Pyrimethmine, Isoniazid, Pyrazinamide and Sulphadoxine
2024	Received CEP from EDQM for Allopurinol (Anti gout)
2024	Received CEP from EDQM for Ambroxol HCL (expectorant cum mucolytic agent)
2024	Enhanced the capacity from 1800 MTPA to 2200 MTPA
2024	Got listed on NSE
2025	Further enhanced the capacity from 2200 MTPA to 2400 MTPA
2025	Received CEP from EDQM for Sulfadimthoxine (Antibiotic)
2026	USFDA inspection completed successfully with zero 483 observation.

Market leadership:

-  Erythromycin salts
-  Pyrazinamide
-  Sulfadoxine
-  Ambroxol HCL
-  Gliclazide
-  Clobetasol Propionate
-  Betamethasone
Dipropionate

Competitive Advantage

- Regulatory approvals
- Environmental health and Safety Compliance (Audited and approved by Multinational companies).
- Well diversified sourcing with backward integration in key products.
- Surplus capacity available
- Financially strong
- Strong R&D capabilities

Product List




<u>Macrolides</u>	<u>Higher Macrolides</u>	<u>Anti Asthamatics</u>	<u>Anti Histamine</u>
1. Erythromycin 11,12 Carbonate 2. Erythromycin Base 3. Erythromycin Estolate 4. Erythromycin Propionate 5. Erythromycin Ethyl Succinate 6. Erythromycin Phosphate 7. Erythromycin Stearate	1. Azithromycin	1. Acebrophylline	Bilsatin
<u>Expectorant</u>	<u>Anti TB</u>	<u>Anti Diabetic</u>	<u>Anti Malarial</u>
1. Ambroxol HCL 2. Acefylline Piperazine	1. Pyrazinamide 2. Isoniazid	1. Gliclazide 2. Vildagliptin 3. Dapagliflozin	1. Sulfadoxine 2. Pyrimethamine 3. Amodiquine
<u>Quinolones</u>	<u>Anti Bacterial</u>	<u>Antibiotic</u>	<u>Anti Gout</u>
1. Moxifloxacin	1. Chloramphenicol 2. Chloramphenicol Palmitate	1. Sulfadimethoxine	1. Allopurinol

Product List



Corticosteroids	
1. Beclomethasone Dipropionate	11. Prednisolone Acetate
2. Betamethasone Acetate	12. Prednisolone Sodium Phosphate
3. Betamethasone Dipropionate	13. Triamcinolone Acetonide
4. Betamethasone Sodium Phosphate	14. Triamcinolone Base
5. Betamethasone Valerate	15. Methyl Prednisolone
6. Clobetasol Propionate	
7. Deflazacort	
8. Dexamethasone Sodium Phosphate	
9. Dexamethasone Acetate	
10. Mometasone Furoate	

Key Management Personnel & Senior Management




Key Management Personnel & Senior Management



Name	Designation	Profile
Mr. Arun Todarwal	Chairman	Fellow member of the ICAI and having practice since 1981. He has handled various professional assignments in India and abroad including Audits, Taxation, International Taxation, Joint Ventures, Due Diligence, Management Consultancy etc. He is well-versed on management issues . He has been a Director several large listed Corporations in India and has had major contribution as Chairman / Member of Audit Committee, Risk Management, Nomination & Remuneration, ESG/CSR, etc.
Mr. Bipin N Shah	Vice Chairman	Involved with Anuh Pharma since inception as a Managing Director. He holds Bachelors degree in Chemical Engineering; and he is also President of Thane Belapur Industries Association.
Mr. Ritesh B Shah	Joint MD	BSc. Chemistry, MBA, handled international marketing for Anuh Pharma for over 20 years, currently involved in overall management of the Company.
Mr. Vivek B Shah	Joint MD	MSc. Biotechnology; handling entire manufacturing operations and R&D since 2009.
Mr. Raju Kotadia	CMO-EM	BSc. Chemistry; part of Anuh Pharma since inception, handling overall sales management of the company.
Mr. Vinayak Shenoy	CMO-MM	MBA in Marketing with over 15 years of experience in APIs and Intermediates, managing global markets including the USA, Europe, CIS, SEA, LATAM, and India and India Regulatory.
Mr. Sanjay Barhate	VP Quality	MSc, M.Phil with chemistry, having versatile experience of 34 years in various functions of Quality at plant and corporate quality function in Bulk drug and formulation dosage forms with reputable MNC.
Mr. Darshan Rampariya	CFO	CA with 17+ years of experience in audit, taxation, corporate finance, Budgetary Controls, Internal Control System, ERP System control, Investor relation.
Mr. Manan Vadhan	CS & CO	ACS with 4+ years of experience in Corporate Secretarial Compliance, Corporate action, SEBI LODR.
Dr. Sanjay Vaidya	GM R&D	25 years of rich experience in the field of industrial process research experience in API molecules.
Mr. Gulshan Sharma	GM Works	B.Tech (Chemical and Pharmaceutical) with 21+ years of experience in API and food industries having expertise in the area of Productivity, Compliance, Quality & Safety.

Latest Shareholding Pattern



Market capitalization (As on 22nd May, 2026)	INR 763 Cr.
Free float market capitalization (As on 22 nd May, 2026)	INR 215 Cr.



03

INFRASTRUCTURE

State of Art manufacturing facility



- Anuh Pharma has a **EUGMP/WHO Pre qualified** approved manufacturing facility at Tarapur spread across **11,400 sq. meters** with 9 API's blocks and 2 intermediate block with total capacity of **2400 MTPA** – this includes new expanded capacity.
- With commissioning of **Zero Liquid Discharge (ZLD)** company stands with huge compliance advantage keeping environmental challenges in mind.

Manufacturing facility Photos



Manufacturing facility Photos



Manufacturing facility Photos



Manufacturing facility Photos



Manufacturing facility Photos



Other Facilitates



The entire facility is equipped with latest Fire Fighting and Safety Measures.



Zero Liquid Discharge Effluent Control system for treating 100% of Generated Pollution.



100% Power Backup via dedicated power line from Power Distributor to our premises.



Adjoining office and a Training Hall for staff.



Green Belt has been provided to reduce the carbon footprint.



Dedicated Research & Development Facility



FACILITATE ACTIVITIES
THAT LEAD TO
CHARACTERIZATION AND
PROFILING OF PRODUCTS.

ANALYTICAL DEV

DEVELOP PROCESSES AND
PRODUCTS.

CHEMICAL SYNTHESIS

LAB SCALE REACTION
BATCHES TO VALIDATE
RESEARCH

PILOT PLANT

IN HOUSE R&D LAB

A dedicated 10,000 SQ. FT. facility to conduct in house experiments and improve our manufacturing process.

We have 16 scientist working at this lab.

APL
empowered by
R&D

NEW PRODUCTS & PROCESSES

Developing new products and processes for future market penetration and expanding product pipeline.

RESEARCH & EXPERIENCE

TWO VALUES FORM THE FOUNDATION OF OUR GROWTH AND SUCCESS



04

FUTURE
OUTLOOK

As we look forward, the fundamental drivers of Anuh Pharma Ltd. remain stronger than ever. The extensive volume expansions across our API lines, coupled with high-value regulatory market growth, have placed us in an well-positioned for sustainable long-term growth. We continue to prioritize process innovations, cost Optimization Strategic Market Diversification focusing on export to reduce currency risk.

Our continued investments in compliance, operational efficiency, and capacity enhancement are creating a strong foundation for long-term sustainable growth. With increasing opportunities in regulated markets, a diversified product portfolio, and improving operational leverage, we remain confident in our ability to deliver consistent value to all stakeholders over the coming years.

The company anticipates a steady growth rate of 15-20% per annum.

Future Outlook – Product under development

Sr. No	Product Name	Therapeutic application
1)	Vonoprazon Fumarate	Anti-Ulcerative
2)	Pretomanid	Anti TB
3)	Edoxaban Tosylate	Anti-coagulant



05

CORPORATE SOCIAL
RESPONSIBILITY

CSR Servicing Society for better tomorrow



Donated to Chhatrapati Shikshan Mandal for Building of Toilet Block for about 3200 student of the School



Donated to Churchgate Lions Service Funds for Promoting Sports for specially challenged children's



Donated to Indian Development Foundation (Project Aashayein) for education to the underprivileged children

CSR Servicing Society for better tomorrow



Donated to Indian Development Foundation (Project Dignity) for providing menstrual hygiene kits and sanitary pads for the needy girl children's



Donated to Late Shri Kantilal Manilal sonawala Charitable Trust for providing education and accommodation to the needy girls



Donated to Greensole Foundation for providing recycled footwear's and masks for the needy children's



Thank You

For specific queries please feel free to contact;
Mr. Darshan Rampariya (CFO)
darshan.r@anuhpharma.com